Advertisement
Advertisement
MRNA
Moderna, Inc. Common Stock
158.83
USDSponsored
+19.94
+14.36%
Aug 25, 15:59 UTC -4
Closed
Pre-Market
157.30
-1.53
-0.96%
MRNA Earnings Reports
Positive Surprise Ratio
MRNA beat 22 of 31 last estimates.
71%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$890.38M
/-$1.22
Implied change from Q2 26 (Revenue/ EPS)
+514.06%
/-38.07%
Implied change from Q3 25 (Revenue/ EPS)
-12.36%
/+139.22%
Moderna, Inc. Common Stock earnings per share and revenue
On Jul 31, 2026, MRNA reported earnings of -1.97 USD per share (EPS) for Q2 26, beating the estimate of -2.12 USD, resulting in a 7.28% surprise. Revenue reached 145.00 million, compared to an expected 105.06 million, with a 38.02% difference. The market reacted with a -5.35% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 11 analysts forecast an EPS of -1.22 USD, with revenue projected to reach 890.38 million USD, implying an decrease of -38.07% EPS, and increase of 514.06% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
Cabaletta Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.34
Surprise
+10.69%
Abeona Therapeutics Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.23
Actual
-$0.35
Surprise
-49.19%
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
Fate Therapeutics, Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.25
Surprise
+8.49%
ProMIS Neurosciences Inc. Common Shares (ON)
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.39
Actual
-$1.28
Surprise
+8.07%
TuHURA Biosciences, Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+5.34%
Outlook Therapeutics, Inc. Common Stock
Report Date
Aug 14, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.09
Surprise
+5.46%
Elutia Inc. Class A Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
Lantern Pharma Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.28
Surprise
+27.76%
FAQ
What were Moderna, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Moderna, Inc. Common Stock reported EPS of -$1.97, beating estimates by 7.28%, and revenue of $145.00M, 38.02% above expectations.
How did the market react to Moderna, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -5.35%, changed from $57.92 before the earnings release to $54.82 the day after.
When is Moderna, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Moderna, Inc. Common Stock's next earnings report?
Based on 11
analysts, Moderna, Inc. Common Stock is expected to report EPS of -$1.22 and revenue of $890.38M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement